Fourth Hospital of Hebei Medical University Trials

Fourth Hospital of Hebei Medical University	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Jiang, Zefei

NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting

408

RoW

HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Breast Cancer

11/21

TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting

287

RoW

TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive,HER2-negative in Advanced Breast Cancer

01/24

12/25

Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting

224

RoW

DB-1303/BNT323, T-DM1

DualityBio Inc., BioNTech SE

HER2-positive Breast Cancer

02/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting

560

RoW

Capivasertib, AZD5363, Fulvestrant

AstraZeneca

Breast Cancer

10/26

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting

1/2

146

RoW

HRS-8080; Dalpiciclib Isethionate Tablets

Shandong Suncadia Medicine Co., Ltd.

Unresectable or Metastatic Breast Cancer

10/25

12/25

NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting

162

SSGJ-705

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Receptor, ErbB-2

12/23

06/24

QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting

RoW

QLS12004

Qilu Pharmaceutical Co., Ltd.

Advanced Solid Tumor

05/24

05/25

Geng, cuizhi

NCT05525767: Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Recruiting

RoW

Bevacizumab

Hebei Medical University Fourth Hospital

Solid Tumor

10/24

12/25

NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting

1072

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast

12/27

07/28

TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting

332

RoW

TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Triple Negative Breast Cancer

07/22

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

NCT05753865: A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Not yet recruiting

454

RoW

SYHX2011, Paclitaxel for injection (albumin-bound)

CSPC Ouyi Pharmaceutical Co., Ltd.

Advanced Breast Cancer

09/24

NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Recruiting

844

RoW

Tamoxifen, Tamoxifen citrate, Toremifene, fareston

Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University

Breast Cancer Female

12/25

NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

254

RoW

SPH4336 Tablets, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

12/25

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

DARLING-02, NCT06107673: Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Recruiting

144

RoW

Dalpiciclib, SHR6390, Aromatase inhibitor, AI, Docetaxel injection, Epirubicin Hydrochloride Injection, Cyclophosphamide injection

Hebei Medical University Fourth Hospital

Breast Cancer

12/24

12/25

NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting

RoW

SPH4336 Tablets

Shanghai Pharmaceuticals Holding Co., Ltd

Breast Cancer Brain Metastases

12/25

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

NCT06375798: Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Recruiting

N/A

620

RoW

radiotherapy

Hebei Medical University Fourth Hospital

Breast Cancer, HER2-negative Breast Cancer

11/26

IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting

N/A

440

RoW

Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra

Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer

04/23

09/24

Lihong, Liu

No trials found

Cuizhi, Geng

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Jiang, Zefei

NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting

408

RoW

HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Breast Cancer

11/21

TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting

287

RoW

TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive,HER2-negative in Advanced Breast Cancer

01/24

12/25

Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting

224

RoW

DB-1303/BNT323, T-DM1

DualityBio Inc., BioNTech SE

HER2-positive Breast Cancer

02/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting

560

RoW

Capivasertib, AZD5363, Fulvestrant

AstraZeneca

Breast Cancer

10/26

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting

1/2

146

RoW

HRS-8080; Dalpiciclib Isethionate Tablets

Shandong Suncadia Medicine Co., Ltd.

Unresectable or Metastatic Breast Cancer

10/25

12/25

NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting

162

SSGJ-705

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Receptor, ErbB-2

12/23

06/24

QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting

RoW

QLS12004

Qilu Pharmaceutical Co., Ltd.

Advanced Solid Tumor

05/24

05/25

Geng, cuizhi

NCT05525767: Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Recruiting

RoW

Bevacizumab

Hebei Medical University Fourth Hospital

Solid Tumor

10/24

12/25

NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting

1072

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast

12/27

07/28

Not yet recruiting

332

RoW

TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Triple Negative Breast Cancer

07/22

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

NCT05753865: A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Not yet recruiting

454

RoW

SYHX2011, Paclitaxel for injection (albumin-bound)

CSPC Ouyi Pharmaceutical Co., Ltd.

Advanced Breast Cancer

09/24

NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Recruiting

844

RoW

Tamoxifen, Tamoxifen citrate, Toremifene, fareston

Breast Cancer Female

12/25

NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

254

RoW

SPH4336 Tablets, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

12/25

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

DARLING-02, NCT06107673: Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Recruiting

144

RoW

Dalpiciclib, SHR6390, Aromatase inhibitor, AI, Docetaxel injection, Epirubicin Hydrochloride Injection, Cyclophosphamide injection

Hebei Medical University Fourth Hospital

Breast Cancer

12/24

12/25

NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting

RoW

SPH4336 Tablets

Shanghai Pharmaceuticals Holding Co., Ltd

Breast Cancer Brain Metastases

12/25

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

08/25

07/26

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

NCT06375798: Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Recruiting

N/A

620

RoW

radiotherapy

Hebei Medical University Fourth Hospital

Breast Cancer, HER2-negative Breast Cancer

11/26

IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting

N/A

440

RoW

Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra

Breast Cancer

04/23

09/24

Lihong, Liu

No trials found

Cuizhi, Geng

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites